Capital Research Global Investors Vertex Pharmaceuticals Inc Transaction History
Capital Research Global Investors
- $463 Billion
- Q3 2024
A detailed history of Capital Research Global Investors transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Capital Research Global Investors holds 9,002,205 shares of VRTX stock, worth $3.65 Billion. This represents 0.9% of its overall portfolio holdings.
Number of Shares
9,002,205
Previous 8,539,339
5.42%
Holding current value
$3.65 Billion
Previous $4 Billion
4.6%
% of portfolio
0.9%
Previous 0.9%
Shares
17 transactions
Others Institutions Holding VRTX
# of Institutions
1,724Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.9 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.39 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.64 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.79 Billion0.23% of portfolio
-
Alliancebernstein L.P. New York, NY7.37MShares$2.99 Billion1.19% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $104B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...